Lyra Therapeutics (LYRA) Payables (2019 - 2025)
Quarterly Payables fell 43.77% to $663000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $663000.0 through Dec 2025, down 43.77% year-over-year, with the annual reading at $663000.0 for FY2025, 43.77% down from the prior year.
Lyra Therapeutics' Payables history spans 7 years, with the latest figure at $663000.0 for Q4 2025.
- Payables came in at $663000.0 for Q4 2025, up from $627000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $5.1 million in Q3 2023 to a low of $627000.0 in Q3 2025.
- The 5-year median for Payables is $2.5 million (2022), against an average of $2.5 million.
- Year-over-year, Payables skyrocketed 449.43% in 2021 and then crashed 86.32% in 2025.
- Lyra Therapeutics' Payables stood at $3.1 million in 2021, then decreased by 16.29% to $2.6 million in 2022, then grew by 19.69% to $3.1 million in 2023, then tumbled by 62.34% to $1.2 million in 2024, then tumbled by 43.77% to $663000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Payables are $663000.0 (Q4 2025), $627000.0 (Q3 2025), and $680000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.03 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Lyra Therapeutics | - | - | - | 663,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 663,000.00 |
| Sep 30, 2025 | 627,000.00 |
| Jun 30, 2025 | 680,000.00 |
| Mar 31, 2025 | 725,000.00 |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 4.97 Mn |
| Mar 31, 2024 | 2.84 Mn |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 5.05 Mn |
| Jun 30, 2023 | 4.19 Mn |
| Mar 31, 2023 | 3.95 Mn |
| Dec 31, 2022 | 2.62 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 2.91 Mn |
| Jun 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | 1.17 Mn |
| Dec 31, 2020 | 922,000.00 |
| Sep 30, 2020 | 530,000.00 |
| Jun 30, 2020 | 1.15 Mn |
| Mar 31, 2020 | 1.36 Mn |
| Dec 31, 2019 | 1.07 Mn |